Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

High-Flow Tracheal Oxygen During Spontaneous Breathing Trial (HFTO-SBT)

16. november 2026 oppdatert av: Gustavo Plotnikow, Argentinian Intensive Care Society

Effect of High-flow Tracheal Oxygen on End-expiratory Lung Impedance and Work of Breathing in Intubated Patients During a Spontaneous Breathing Trial.

The purpose of this study is to find out whether high-flow tracheal oxygen (HFTO) delivered at flows greater than 60 L/min can increase end-expiratory lung volume (EELV) in intubated patients during a spontaneous breathing trial (SBT).

Weaning from mechanical ventilation can be difficult, especially in patients at higher risk of failure. During an SBT, losing positive end-expiratory pressure (PEEP) can cause the lungs to lose volume and make breathing harder by increasing the work of breathing (WOB). HFTO may help reduce the work of breathing, but previous studies using flows of 30-60 L/min did not consistently show an increase in EELV. Higher flows may create more airway pressure.

Therefore, the main question this study is trying to answer is: In intubated patients during an SBT, does HFTO at flows greater than 60 L/min increase EELV? The hypothesis is that HFTO at flows above 60 L/min will increase EELV during the SBT.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, 1280AEB
        • Rekruttering
        • Hospital Británico de Buenos Aires
        • Ta kontakt med:
          • Gustavo Adrián Plotnikow, PhD, Head of Department
          • Telefonnummer: +54 9 11 6454 3771
          • E-post: gplotnikow@gmail.com

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • Invasive mechanical ventilation ≥ 24 hours
  • Presence of esophageal balloon catheter
  • Meets criteria to start an SBT
  • Signed informed consent by patient or responsible family member

Exclusion Criteria:

  • Neuromuscular or neurodegenerative disease
  • contraindication to electrical impedance tomography (e.g., implantable defibrillator)
  • Impossible to place EIT electrode belt (e.g., wound dressings or chest drains)

Elimination Criteria:

  • Flow intolerance
  • Behavioral/cognitive alterations that interrupt measurements in two consecutive attempts.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sequence A (HFTO 50 → HFTO 70)

Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT):

T-piece (baseline) - 15 minutes

High-flow tracheal oxygen (HFTO) at 50 L/min - 15 minutes

Washout on T-piece - 15 minutes

HFTO at 70 L/min - 15 minutes

Washout on T-piece - 15 minutes

Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes

Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.

Eksperimentell: Sequence B (HFTO 70 → HFTO 50)

Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT):

T-piece (baseline) - 15 minutes

High-flow tracheal oxygen (HFTO) at 70 L/min - 15 minutes

Washout on T-piece - 15 minutes

HFTO at 50 L/min - 15 minutes

Washout on T-piece - 15 minutes

Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes

Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters: ΔPes, PTPes, PTPes-min), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in end-expiratory lung impedance (EELI) during spontaneous breathing trial
Tidsramme: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in global end-expiratory lung impedance (ΔEELI; arbitrary units), measured by electrical impedance tomography (EIT), expressed as tidal variation of the first stable respiratory cycle, among four conditions in intubated adult patients during a spontaneous breathing trial: T-piece, high-flow tracheal oxygen (HFTO) at 50 L/min, HFTO at 70 L/min, and pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O. Because this is a randomized crossover study, the primary comparison is within-subject across conditions.

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in esophageal pressure swing
Tidsramme: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in esophageal pressure swing (ΔPes; units cmH2O) across conditions (T-piece, HFTO 50 L/min, HFTO 70 L/min, PSV 7 cmH₂O / PEEP 0 cmH₂O).

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
Change in Diaphragmatic Thickening Fraction (DTF)
Tidsramme: Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.

Change in diaphragmatic thickening fraction (DTF; Units percentage) measured by ultrasonography, calculated as:

DTF = [(thickness at end-inspiration - thickness at end-expiration) / thickness at end-expiration] × 100.

Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
Respiratory rate
Tidsramme: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.

Number of ventilatory cicles per minute

Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Days of invasive mechanical ventilation to weaning
Tidsramme: Baseline

Days of invasive mechanical ventilation from the intubation to the first weaning attempt

Baseline
ICU length of stay
Tidsramme: From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.

Duration of stay in the intensive care unit (ICU) from ICU admission to ICU discharge or death, whichever occurs first (Units; days)

From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.
ICU mortality
Tidsramme: Through ICU discharge or up to [28 days] after enrollment/randomization.

Number of participants who died in the ICU.

Through ICU discharge or up to [28 days] after enrollment/randomization.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

31. desember 2026

Studiet fullført (Antatt)

31. mars 2027

Datoer for studieregistrering

Først innsendt

29. september 2026

Først innsendt som oppfylte QC-kriteriene

2. oktober 2026

Først lagt ut (Faktiske)

7. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere